Health beliefs and vaccine costs regarding human papillomavirus (HPV) vaccination among a U.S. national sample of adult women

Preventive Medicine

Volumn 54, Issue 3-4, 2012, Pages 277-279

  Liau, Adrian ^a   Stupiansky, Nathan W ^a   Rosenthal, Susan L ^b   Zimet, Gregory D ^a  

^a INDIANA UNIVERSITY   (United States)

^b New York Presbyterian Morgan Stanley Children's Hospital ^*  (United States)

Author keywords

Attitude to health; Health care costs; Human papillomavirus vaccines; Women's health

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; ATTITUDE TO HEALTH; DEMOGRAPHY; DRUG COST; FEMALE; HEALTH BELIEF; HEALTH CARE COST; HUMAN; HUMAN PAPILLOMAVIRUS VACCINATION; INTERNET; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PREDICTION; PRIORITY JOURNAL; SOCIOECONOMICS; UNITED STATES; VACCINATION;

ADULT; ATTITUDE TO HEALTH; DATA COLLECTION; FEMALE; HEALTH CARE COSTS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LINEAR MODELS; MIDDLE AGED; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; UNITED STATES;

EID: 84858997153     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2012.02.002     Document Type: Article

References (14)

1. CSL Australia Gardasil® Available from, Accessed 12 December 2011. http://www.csl.com.au/s1/cs/auhq/1196562765747/Web_Product_C/1196562633137/ProductDetail.htm.
2. Dunne E.F., Sternberg M., Markowitz L.E., McQuillan G., Swan D., Patel S., Unger E.R. Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States-National Health and Nutrition Examination survey, 2003-2006: opportunity to measure HPV vaccine impact?. J. Infect. Dis. 2011, 204:562-565.
3. GlaxoSmithKline Australia Cervarix® Available from, Accessed 12 December 2011. http://www.gsk.com.au/products_vaccines_detail.aspx?view=122.
4. Kenny D.A. Statistics for the Social and Behavioral Sciences 1987, Little, Brown & Company, New York.
5. Lenehan J.G., Leonard K.C., Nandra S., Isaacs C.R., Mathew A., Fisher W.A. Women's knowledge, attitudes, and intentions concerning human papillomavirus vaccination: findings of a waiting room survey of obstetrics-gynaecology outpatients. J. Obstet. Gynaecol. Can. 2008, 30:489-499.
6. Merck Canada Health Canada approves Gardasil® for Women up to Age 45 Available from, Accessed 30 August 2011. http://www.merck.ca/assets/en/pdf/press/product_info/gardasil/press_releases/Gardasil_Adult_Women_Release_EN.pdf.
7. Muñoz N., Manalastas R., Pitisuttithum P., Tresukosol D., Monsonego J., Ault K., Clavel C., Luna J., Myers E., et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009, 373:1949-1957.
8. Newman P.A., Logie C. HIV vaccine acceptability: a systematic review and meta-analysis. AIDS 2010, 24:1749-1756.
9. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.-N., Apter D., Kitchener H., Castellsague X., Teixeira J.D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
10. Sauvageau C., Duval B., Gilca V., Lavoie F., Ouakki M. Human papilloma virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada. BMC Public Health 2007, 7:304.
11. Stupiansky N.W., Rosenthal S.L., Wiehe S.E., Zimet G.D. Human papillomavirus vaccine acceptability among a national sample of adult women in the USA. Sex. Health 2010, 7:304-309.
12. Sturm L.A., Mays R.M., Zimet G.D. Parental beliefs and decision making about child and adolescent immunization: from polio to sexually transmitted infections. J. Dev. Behav. Pediatr. 2005, 26:441-452.
13. Villa L.L., Costa R.L.R., Petta C.A., Andrade R.P., Paavonen J., Iversen O.-E., Olsson S.-E., Hoye J., Steinwall M., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5years of follow-up. Br. J. Cancer 2006, 95:1459-1466.
14. Zimet G.D., Perkins S.M., Winston Y., Kee R. Predictors of first and second dose acceptance of hepatitis B vaccine among STD clinic patients. Int. J. STD AIDS 2008, 19:246-250.